Crescent Biopharma Inc
Company Profile
Business description
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
Contact
221 Crescent Street
Suite 105, Building 23
WalthamMA02453
USAT: +1 617 430-5595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,747.50 | 10.40 | -0.12% |
| CAC 40 | 7,656.12 | 27.61 | -0.36% |
| DAX 40 | 23,317.81 | 116.84 | -0.50% |
| Dow JONES (US) | 42,171.66 | 44.14 | -0.10% |
| FTSE 100 | 8,843.47 | 9.44 | 0.11% |
| HKSE | 23,269.81 | 440.88 | -1.86% |
| NASDAQ | 19,546.27 | 25.18 | 0.13% |
| Nikkei 225 | 38,637.94 | 247.21 | -0.64% |
| NZX 50 Index | 12,594.31 | 33.01 | -0.26% |
| S&P 500 | 5,980.87 | 1.85 | -0.03% |
| S&P/ASX 200 | 8,528.80 | 2.40 | -0.03% |
| SSE Composite Index | 3,359.78 | 29.03 | -0.86% |